IGC Pharma

We are a clinical stage pharmaceutical company, formerly known as India Globalization Capital, Inc.

About IGC Pharma (dba IGC):

IGC Pharma is an AI-powered, clinical-stage biotechnology company focused on developing innovative treatments for Alzheimer's disease and transforming patient care with fast-acting, safe, and effective solutions. Our portfolio includes the TGR family, including TGR-63, which targets amyloid plaques, a hallmark of Alzheimer's. The IGC-C and IGC-M platforms are advancing in preclinical studies, focusing on metabolic disorders, tau proteins, early plaque formation, and multiple disease hallmarks. Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681). Clinical data for IGC-AD1 demonstrated that it has the potential to transform patient care by offering faster-acting and more effective relief compared to traditional medications. Additionally, our AI models are designed to predict potential biomarkers for the early detection of Alzheimer's, optimize clinical trials, and predict receptor affinity, among others. With 28 patent filings and a commitment to innovation, IGC Pharma is dedicated to advancing pharmaceutical treatments and improving the lives of those affected by Alzheimer's and related conditions.

01/26/2026

Patients and caregivers are at the heart of everything we do.

Every journey with Alzheimer’s is deeply personal. Behind each diagnosis is a family learning, adapting, and caring with strength and compassion.

At IGC Pharma, our work is guided by respect for patients, support for caregivers, and a shared commitment to doing better, together.

01/23/2026

IGC Pharma adds Integrative Clinical Trials, LLC, located in Brooklyn, New York, as a new clinical site participating in its Phase 2 CALMA clinical trial.

This new site conducts research across a broad range of central nervous system disorders, including Alzheimer’s disease and mild cognitive impairment, and supports IGC Pharma’s focus on high-quality data generation, efficient trial ex*****on, and patient engagement.

Read the full press release: https://finance.yahoo.com/news/igc-pharma-expands-phase-2-140000971.html
hashtag hashtag hashtag hashtag

01/13/2026

Caring for someone with Alzheimer’s isn’t always easy, especially when behaviors change unexpectedly.

Moments of agitation are often a sign that something feels wrong or overwhelming. Approaching these moments with patience and compassion can make a meaningful difference for both caregivers and those they care for.

01/08/2026

Every memory, thought, and emotion depends on how well our neurons communicate.

In Alzheimer’s, that connection begins to break down; a process scientists call neurodegeneration.

Understanding how this happens brings us closer to addressing the changes that lead to memory loss and cognitive decline.

🔗 Learn more in our Science Spotlight: https://igcpharma.com/is-neurodegeneration-the-root-cause-of-alzheimers-disease/

12/30/2025

As we close out the year, we want to thank everyone who has been part of the IGC Pharma community: our teams, researchers, caregivers, clinical partners, collaborators, and all who support our mission.

In 2025, we strengthened our work in Alzheimer’s research, continued advancing important projects across science and technology, and built partnerships that help move progress forward with purpose.

We’re grateful for every step taken together this year.

Wishing you a meaningful and hopeful 2026.

12/18/2025

Agitation can be one of the hardest symptoms of Alzheimer’s, not just for patients, but also for families and caregivers.

It may appear as restlessness, pacing, aggression, or repetitive movements, often caused by changes in the brain’s communication and chemistry.

At IGC Pharma, we’re studying IGC-AD1, an investigational oral liquid that aims to manage agitation in Alzheimer’s disease.

Learn more: igcpharma.com/igc-ad1

12/10/2025

IGC Pharma is sharing recent updates, including continued progress in the Phase 2 CALMA trial for agitation in Alzheimer’s disease and newly issued analyst coverage from Ascendiant Capital Markets.

The CALMA study continues to advance across clinical sites in the U.S. and Canada, supported by the Company’s hybrid recruitment approach. Ascendiant’s updated report provides additional perspective on IGC Pharma’s development path and anticipated milestones.

Read CALMA's full press release here: https://finance.yahoo.com/news/igc-pharma-reports-65-patient-140000321.html

Read the full analyst report here: https://ascendiant.com/research-reports/igc-q2-fy26/

12/05/2025

Today, Paola Ruiz, Senior Manager of AI & Software, together with CEO Ram Mukunda, recently shared a live demo of AHA at AlzInsights Summit 2, an event hosted by the Alzheimer’s Disease Data Initiative.

AHA is being developed to explore how agentic AI may help harmonize diverse Alzheimer’s datasets and support research insights.

We’re honored that this work has been recognized with a spot in the semi-finals of the Alzheimer’s Insights AI Prize.

Grateful to be part of a community working to advance understanding and innovation in Alzheimer’s research.

12/03/2025

IGC Pharma announces the publication of Caring for a Loved One with Alzheimer’s Disease: Firsthand Experiences, a comprehensive caregiver-focused book that combines educational chapters on Alzheimer’s disease with powerful first-person stories from caregivers. Sponsored by IGC Pharma, this resource supports our mission to advance scientific innovation while empowering caregivers and communities impacted by Alzheimer’s disease.

Download the book (English):https://igcpharma.com/wp-content/uploads/2025/12/Alzheimers_Caregivers-English-_Version.pdf

Download the book (Spanish):https://igcpharma.com/wp-content/uploads/2025/12/Cuidadores_Alzheimer_Version_en_Espanol.pdf

11/14/2025

U.S. patent expands IGC Pharma’s intellectual property portfolio and supports our continued work to develop safer, more effective treatments that address both behavioral symptoms and core disease mechanisms of Alzheimer’s disease.

11/11/2025

On Veterans Day, we pause to honor the courage, resilience, and dedication of those who served.

Their strength reminds us why advancing care and understanding matter.

At IGC Pharma, we’re proud to support continued awareness of brain health among veterans.

11/10/2025

IGC Pharma will host its Mid-Year Fiscal 2026 Shareholder Update Call on November 17 at 11:00 a.m. ET to review operational progress and financial results for the quarter ended September 30, 2025.

Join us as we review our second quarter and mid-year results for fiscal 2026

U.S. dial-in: (888) 506-0062
International: (973) 528-0011
Access Code: 146922
Live webcast: https://www.webcaster5.com/Webcast/Page/2938/53104

A replay of the call will be available at the link above until Thursday, February 12, 2026.

Address

Potomac, MD

Telephone

+13019830998

Website

https://igcpharma.com/

Alerts

Be the first to know and let us send you an email when IGC Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.